The Effect of Priming Intravenous Rocuronium on Fentanyl-Induced Coughing
Fentanyl-induced Coughing
About this trial
This is an interventional prevention trial for Fentanyl-induced Coughing focused on measuring fentanyl-induced coughing, rocuronium
Eligibility Criteria
Inclusion Criteria:
- 260 ASA I-II patients,
- aged between 18 and 80 years, and undergoing various elective surgeries at Taichung Armed Forces General Hospital.
Exclusion Criteria:
- a history of asthma,
- chronic cough,
- smoking,
- upper respiratory tract infection in the previous 2 weeks, and
- medication containing angiotensin-converting enzyme inhibitors or anesthetic premedication.
Sites / Locations
- Taichung Armed Forces General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Rocuronium, fentanyl-induced cough, normal saline
Normal saline
All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).